CTLA4 and myocarditis: Mortality reported from these cases of myocarditis ranged from 36% for patients treated with anti-PD-1 or anti-PD-L1 antibodies to 67% for patients treated with combination anti-CTLA-4 and anti-PD1/PD-L1 therapy.